<DOC>
	<DOCNO>NCT00325962</DOCNO>
	<brief_summary>The purpose study determine whether 6R-BH4 ( sapropterin dihydrochloride ) safe effective treatment poorly control hypertension presence absence type 2 diabetes .</brief_summary>
	<brief_title>A Study Effects 6R-BH4 Blood Pressure Subjects With Poorly Controlled Systemic Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Willing able provide write , sign informed consent nature study explain prior researchrelated procedure . At least 18 year age . Willing able comply studyrelated procedure . History document essential hypertension ( BP great equal 140 mm Hg systolic and/or 90 mm Hg diastolic measure 2 separate occasion ) . Have poorly control hypertension despite use least two conventional antihypertensive agent different mechanism action take concurrently consistently least 3 month randomization . ( Note : Antihypertensive agent may individual combined single medication . ) During twoweek screening period , mean SBP mean DBP fall within follow range : Mean SBP 135 160 mm Hg Mean DBP 85 110 mm Hg Sexually active subject must willing use acceptable method contraception participate study . Females childbearing potential must negative pregnancy test screen willing additional pregnancy test study . Individuals diabetic cohort must meet additional criterion : Documented history type 2 diabetes treat use therapy least 3 month . Previous treatment formulation BH4 . Known allergy hypersensitivity excipient 6RBH4 . Known secondary cause hypertension . Concurrent disease condition would interfere study participation safety bleed disorder , history syncope vertigo , severe gastrointestinal reflux disease ( GERD ) , symptomatic coronary peripheral vascular disease , arrhythmia , organ transplant , organ failure , type 1 diabetes mellitus . Any sever comorbid condition would limit life expectancy le 6 month . Serum creatinine &gt; 2.0mg/dL hepatic enzyme level 2 time upper limit normal . Requirement concomitant treatment drug know inhibit folate metabolism ( e.g. , methotrexate ) . Concomitant treatment levodopa . Concomitant treatment phosphodiesterase ( PDE ) 5 inhibitor ( e.g. , Viagra ( R ) , Cialis ( R ) , Levitra ( R ) , Revatio ( TM ) PDE 3 inhibitor ( e.g. , cilostazol , milrinone , vesnarinone ) . ) Use investigational product device within 30 day prior screen , requirement investigational agent prior completion schedule study assessment . Pregnant breastfeed screen plan become pregnant ( subject partner ) time study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>6R-BH4</keyword>
	<keyword>BH4</keyword>
	<keyword>BH4 deficiency</keyword>
	<keyword>sapropterin dihydrochloride</keyword>
	<keyword>endothelial dysfunction</keyword>
	<keyword>NO</keyword>
	<keyword>Nitric Oxide</keyword>
</DOC>